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The effects of metrifonate, a second generation cholinesterase
inhibitor, were examined on CA1 pyramidal neurons from hip-
pocampal slices of young and aging rabbits using current-
clamp, intracellular recording techniques. Bath perfusion of
metrifonate (10–200 mM) dose-dependently decreased both
postburst afterhyperpolarization (AHP) and spike frequency ad-
aptation (accommodation) in neurons from young and aging
rabbits (AHP: p , 0.002, young; p , 0.050, aging; accommo-
dation: p , 0.024, young; p , 0.001, aging). These reductions
were mediated by muscarinic cholinergic transmission, be-
cause they were blocked by addition of atropine (1 mM) to the
perfusate. The effects of chronic metrifonate treatment (12
mg/kg for 3 weeks) on CA1 neurons of aging rabbits were also
examined ex vivo. Neurons from aging rabbits chronically
treated with metrifonate had significantly reduced spike fre-
quency accommodation, compared with vehicle-treated rab-
bits. Chronic metrifonate treatment did not result in a desensi-
tization to metrifonate ex vivo, because bath perfusion of
metrifonate (50 mM) significantly decreased the AHP and ac-
commodation in neurons from both chronically metrifonate-
and vehicle-treated aging rabbits. We propose that the facili-
tating effect of chronic metrifonate treatment on acquisition of
hippocampus-dependent tasks such as trace eyeblink condi-
tioning by aging subjects may be caused by this increased
excitability of CA1 pyramidal neurons.
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The learning and cognitive deficits observed in normal aging and
in Alzheimer’s disease (AD) patients are hypothesized to be
partly caused by the loss of cholinergic neurons in the basal
forebrain. It has been suggested that these deficits may be allevi-
ated by improving cholinergic function (Bartus et al., 1982; Hal-
lak and Giacobini, 1989). Currently, tacrine and donepezil (Unit-
ed States) and exelon and galanthamine (Europe) are clinically
approved cholinesterase inhibitors (ChEI) used for treating AD.
Further research is ongoing to develop more effective ChEIs with
fewer side effects (Cummings et al., 1998; Morris et al., 1998;
Pettigrew et al., 1998).
One new generation ChEI currently in phase III clinical trials
is metrifonate, an organophosphate compound that is considered
to be a prodrug, because it is transformed nonenzymatically to
0,0-dimethyl 2,2-dichlorovinyl phosphate, which produces the
long-lasting inhibition of both acetylcholinesterase (AChE) and
butyrylcholinesterase (Nordgren et al., 1978; Schmidt et al.,
1998). More importantly, extended treatment with metrifonate
has been shown to result in an increased acetylcholine (ACh)
level with fewer, less severe side effects than other ChEIs (Soin-
inen et al., 1990; Becker et al., 1991; Sihver et al., 1997). Behav-
ioral experiments have demonstrated that metrifonate treatment
improved cognitive performance in AD patients (Cummings et
al., 1998; Morris et al., 1998; Pettigrew et al., 1998), reduced both
scopolamine- and basal forebrain lesion-induced deficits in water
maze and passive avoidance tasks in rats (Itoh et al., 1997), and
rescued object recognition in aging rats (Scali et al., 1997). Re-
cently, our laboratory demonstrated that metrifonate treatment
facilitated acquisition of trace (hippocampus-dependent) eye-
blink conditioning in aging rabbits (Kronforst-Collins et al.,
1997a,b).
Although there are numerous behavioral experimental reports
concerning metrifonate, there is no electrophysiological literature
concerning the effects of metrifonate, which may be relevant to
the mechanism of actions mediating its potentially valuable ther-
apeutic benefits. Several in vitro experiments have demonstrated
that application of ACh, muscarinic agonists, or anticholinester-
ases increased neuronal excitability [reduced postburst afterhy-
perpolarization (AHP) and spike frequency adaptation (accom-
modation)] of hippocampal pyramidal neurons (Bernardo and
Prince, 1981, 1982; Cole and Nicoll, 1983, 1984a,b; Madison and
Nicoll, 1984; Halliwell, 1990; Taylor and Griffith, 1993; Pedarzani
and Storm, 1996). Furthermore, both the AHP and accommoda-
tion were reduced in CA1 neurons from young and aging rabbits
that acquired eyeblink conditioning, but not in trained rabbits
that did not learn (Disterhoft et al., 1986, 1988, 1996; Coulter et
al., 1989; de Jonge et al., 1990; Moyer et al., 1996; Thompson et
al., 1996b). Also, both the AHP and accommodation are greater
in CA1 neurons from aging rabbits (Moyer et al., 1992) and rats
(Landfield and Pitler, 1984; Potier et al., 1992) as compared with
that from young animals.
The current study was designed to determine (1) the effects, (2)
the effective concentrations of bath application of metrifonate on
CA1 neurons from hippocampal slices of young and aging rabbits,
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(3) whether chronic metrifonate treatment in aging rabbits alters
basal CA1 excitability ex vivo, and (4) if the chronic metrifonate
treatment has a saturating, desensitizing effect.
MATERIALS AND METHODS
Subjects. Young (,3 month) and aging (.36 month) female New Zea-
land albino rabbits (Oryctolagus cuniculus) were used as subjects. We
chose to study these two age groups for the following reasons: (1)
previous work in our laboratory has established that rabbits, 301 months
old, are impaired in acquiring the trace eyeblink conditioning task
(Thompson et al., 1996a), and similar impairments have been observed in
aging humans (Woodruff-Pak and Thompson, 1988); (2) we have dem-
onstrated that hippocampal pyramidal neurons from aging rabbits are
less excitable than those from young animals and possibly contribute to
the age-related learning deficits (see results; Moyer et al., 1992); (3) the
effects of bath application of metrifonate in vitro have not been explored
in either age group; and (4) previous work has demonstrated that met-
rifonate in vivo unequally increased the ACh levels in the hippocampus
of young and aging subjects (Scali et al., 1997), thus, bath application of
metrifonate in vitro may also yield unequal effects on the hippocampal
slices from young and aging subjects. Each subject was housed in an
individual cage in a climate-controlled room on a 12 hr light /dark cycle
with ad libitum access to food and water. The animal care was provided
and managed by the animal care personnel of Northwestern University
after the guidelines established by the university and the United States
Department of Agriculture.
Slice preparation. Hippocampal slices were made using procedures
previously described (Moyer et al., 1996; Thompson et al., 1996b). The
rabbits were anesthetized with halothane in a fume hood and killed by
decapitation. The brain was quickly exposed, hemisected in situ, re-
moved, and immersed in an ice-cold (,1°C) oxygenated sucrose–
artificial CSF (aCSF) that minimizes anoxic impact during slice prepa-
ration (Aghajanian and Rasmussen, 1989) (sucrose–aCSF composition
in mM: 248 sucrose, 26 NaHCO3 , 10 D-glucose, 3 KCl, 2.4 CaCl2 , 1.3
MgSO4 , and 1.24 NaH2PO4 , gassed with 95% O2 and 5% CO2 , pH 7.4).
After ;4 min in the ice-cold sucrose–aCSF, both hippocampi were
dissected out, cut into two 5 mm transverse chunks, and glued to a small,
chilled chamber that was filled with the ice-cold sucrose–aCSF. Slices
(400 mM) were cut using a vibratome and placed in a holding chamber
filled with normal aCSF (124 mM NaCl substituted for sucrose) at room
temperature (;22°C) for at least 45 min before being individually trans-
ferred to the submersion chamber (Medical Systems, Greenvale, NY) for
recording.
Electrophysiolog ical recording and data analysis. Intracellular record-
ings were made from CA1 pyramidal neurons using an Axoclamp 2A
amplifier (Axon Instruments, Foster City, CA) and previously published
protocols (Moyer et al., 1996; Thompson et al., 1996b). Microelectrodes
were made from a thin-walled capillary glass and filled with 3 M KCl
(30–50 MV). Slices were individually transferred to a submersion cham-
ber and continuously perfused (;1.75 ml/min) with oxygenated aCSF
heated to 31°C. A cell was classified as a CA1 neuron and included in the
study if it had little spontaneous activity at rest, a stable resting mem-
brane potential less than 260 mV, an action potential duration .1.2
msec from rise threshold to recrossing the resting potential, an input
resistance $20 MV, and an action potential amplitude .80 mV from
rest. After the neuron had stabilized for 5 min after the initial impale-
ment, the biophysical membrane properties were measured with the
neuron held near 268 mV (using less than 60.2 nA) to ensure that the
differences observed were not caused by voltage-dependent membrane
properties.
The baseline membrane properties were measured in normal aCSF.
The current–voltage (I–V ) relations were studied by using 400 msec
current steps (range, 21.0 to 10.2 nA). The input resistance was calcu-
lated by measuring the plateau voltage deflection during the last 75 msec
of a 400 msec, 20.2 nA hyperpolarizing step. The AHP was studied using
a 100 msec depolarizing current step that reliably elicited a burst of four
action potentials. The duration of the AHP was measured as the time
required for the membrane potential to return to the baseline potential
for at least 10 msec from the 100 msec depolarizing current step offset.
The peak AHP amplitude was calculated as the maximum negative
voltage deflection from the baseline potential during the first 250 msec
after the current offset. The integrated area of the AHP was calculated
from the current offset for the entire duration of the AHP. A total of five
AHP measurements were made from each neuron at 30 sec intervals.
Accommodation was studied using an 800 msec depolarizing current step
of the same stimulus intensity used to evoke the AHP. The number of
action potentials elicited was noted for three trials at 30 sec intervals.
After the baseline measurements were recorded, the perfusate was
changed to an aCSF containing carbachol (500–1000 nM), eserine (500–
5000 nM), metrifonate (1–200 mM), atropine (1 mM; by itself or added to
the previously mentioned drugs), or vehicle (normal aCSF). The exper-
imenter was blind to the identity of the perfusate until the end of data
collection. The neuron was held near 275 mV (or at rest, if the resting
membrane potential was less than 275 mV) for 10 min and allowed to
stabilize during the changing of the perfusate. After the 10 min interval,
the biophysical measurements were repeated. In some cases, the neuron
was subject to another perfusate, or a wash-out of the perfusate was
attempted (blind procedures were used). At the end of the experiment,
the resting membrane potential was determined as the difference in the
potential before and after the microelectrode withdrawal from the neu-
ron. The slice was changed if a cell was lost during an experiment, if more
than five penetrating attempts were made, or after the completion of the
experiment.
All data were digitized and analyzed on-line using a Lab NB or
NB-MIO-16H and DMA-2800 boards (National Instruments, Austin,
TX) interfaced to Power Macintosh computers using custom software
routines written in LabView (National Instruments). Analog-to-digital
sampling rates were 10 kHz for I–V, AHP, and accommodation measure-
ments and 1–2 kHz for the resting membrane potentials. Complete
analyses were performed off-line using procedures developed with Lab-
View. Statistical analyses were performed using paired t tests and
ANOVA (StatView; Abacus Concepts, Berkeley, CA). Significant main
effects were evaluated using Scheffe’s post hoc tests. All data are reported
as the mean 6 SEM.
Chronic treatment with metrifonate. Using similar procedures to those
previously published (Kronforst-Collins et al., 1997b), aging (.40
month) rabbits received 15 oral doses (5 d of treatment followed by 2 d
of no treatment repeated for three weeks) of either 12 mg/kg metrifonate
dissolved in a 100 mM sodium citrate vehicle (n 5 4; mean age, 41.31 6
0.06 months) or vehicle alone (n 5 3; mean age, 41.00 6 0.13 months).
Previously, 12 mg/kg metrifonate was found to produce optimum facil-
itation of trace eyeblink conditioning in aging rabbits (Kronforst-Collins
et al., 1997a,b). Blood samples were taken from all subjects 1 d before the
start of treatment and ;2 hr before killing. Twenty-four hours after the
last treatment, hippocampal slices were prepared, and CA1 neurons were
recorded from as described above. AHP, accommodation, and input
resistance were measured sequentially as described above in aCSF, aCSF
with 50 mM metrifonate, and aCSF with 50 mM metrifonate plus 1 mM
atropine perfusates with 10 min intervals between changes in the per-
fusate. The experimenter was blind to the identity of the chronic treat-
ment during the daily administration, blood sampling, electrophysiolog-
ical recordings, and data reduction until the end of the experiment.
ChE inhibition measurement. The level of ChE inhibition was measured
using procedures described by Kronforst-Collins et al. (1997a,b). The
subjects were given fentanyl citrate and droperidol anesthesia (0.5 ml/kg,
i.m.) before blood sampling. Each blood sample was collected in two 1.5
ml aliquot tubes each containing 50 ml of heparin. The samples were
centrifuged at 1000 3 g, 4°C for 15 min. The plasma and red blood cells
(RBCs) were separated and stored at 280°C until ChE inhibition assays
were performed. It has been previously demonstrated that the level of
RBC AChE activity in the rabbit is significantly correlated with that of
the ChE of the brain (Kronforst-Collins et al., 1997a). Thus, the mean
percentages of ChE inhibition values were calculated for the RBCs for
each subject. The ChE inhibition values were analyzed with ANOVA and
unpaired t tests.
Drugs. Metrifonate was a gift from Bayer Corporation (West Haven,
CT). All other drugs used were purchased from Sigma (St. Louis, MO).
Eserine and atropine stocks were made and used in near darkness. Stock
solution of metrifonate (pH ;4.0) was prepared weekly and refrigerated
(;3°C) along with the other stock solutions.
RESULTS
Metrifonate decreased the AHP amplitude and area
Metrifonate significantly decreased the AHP peak amplitude and
integrated area in CA1 neurons from both young and aging
subjects (Figs. 1D, 2A; Table 1). Significant reductions of the
AHP amplitude and area were produced with 10 mM metrifonate
in the neurons from young rabbits ( p , 0.006; p , 0.046, respec-
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tively). No depression was observed in the neurons from aging
rabbits at this concentration ( p . 0.309; p . 0.178, respectively).
Instead, a significant reduction of the AHP amplitude was ob-
served with 50 mM metrifonate in the neurons from aging rabbits
( p , 0.009); the AHP area was not significantly reduced, al-
though a trend toward the reduction was observed ( p , 0.074).
Decrements in both AHP peak amplitude and integrated area for
the neurons from aging rabbits were observed with 100 mM
metrifonate ( p , 0.002; p , 0.001, respectively). The neurons
from young rabbits depolarized to levels at which regular bursts of
spontaneous action potentials made the biophysical measurements
impossible at 100 mM metrifonate, and eventual cell death occurred
in all but one of five neurons attempted. No such effects were
observed in neurons from aging rabbits (tested up to 200 mM).
Metrifonate reduced the AHP peak amplitude in the neurons
from both young and aging rabbits in a dose-dependent manner
(F(4,20) 5 6.048, p , 0.002; F(3,31) 5 2.920, p , 0.050; respective-
ly). Scheffe’s post hoc test revealed that the percent AHP peak
amplitude reduction was significantly greater at both 50 and 100
mM metrifonate compared with 1 mM in the neurons from young
rabbits ( p , 0.019; p , 0.026, respectively). Also, ANOVA
revealed that there was a significant difference in the mean
baseline AHP peak amplitudes between the neurons from young
(3.76 6 0.33; n 5 25) and aging (4.90 6 0.30, n 5 37) rabbits
(F(1,60) 5 6.29; p , 0.015) (Moyer et al., 1992).
Metrifonate also shortened the duration of the AHP. However,
this effect was significant only at 100 and 200 mM metrifonate for
neurons from the aging rabbits ( p , 0.001; p , 0.025,
respectively).
Metrifonate decreased spike
frequency accommodation
Metrifonate significantly decreased the accommodation of CA1
neurons from both young and aging rabbits (Figs. 1, 2B; Table 1).
In neurons from the young rabbits, significant accommodation
decrement was observed at 50 mM metrifonate ( p , 0.001).
Lower concentrations of metrifonate were not effective; a higher
concentration (100 mM tested) caused instability and cell death in
neurons from young animals. In neurons from the aging rabbits,
Figure 2. Bath application of metrifonate significantly increased neuro-
nal excitability in CA1 neurons from both naive young and aging subjects.
A, Mean percent AHP peak amplitude reduction from baseline after
perfusion with metrifonate at various concentrations for both age groups
is illustrated. In B, the mean percent change in number of action poten-
tials elicited during the accommodation pulse from baseline after perfu-
sion with metrifonate at various concentrations for both age groups are
illustrated (mean 6 SEM).
Figure 1. Bath application of metrifonate signifi-
cantly decreased the accommodation and the post-
burst AHP in CA1 neurons from aging subjects. An
example of the effect of metrifonate on accommoda-
tion is illustrated in A–C (same neuron). A depicts a
typical response elicited during the 800 msec depo-
larizing pulse obtained in baseline measures. B illus-
trates a typical increase in number of action poten-
tials elicited during the accommodation pulse after
the perfusate has been changed to 200 mM metrifon-
ate. C depicts a typical decrease in the number of
action potentials elicited after the perfusate has been
changed to a combination of 200 mM metrifonate and
1 mM atropine, indicating that the metrifonate effect
is muscarinic. An example of the AHP decrement
observed after the perfusate has been changed to a
100 mM metrifonate in CA1 neurons from aging sub-
jects is illustrated in D (scales for B and C are the
same as that of A).
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significant reductions were observed at concentrations of 50 mM
and higher metrifonate (Table 1). The accommodation decre-
ment was dose-dependent in neurons from the aging rabbits
(F(3,32) 5 7.11; p , 0.001) with greater reduction observed at 200
mM compared with 10 and 50 mM metrifonate ( p , 0.035; p ,
0.013, respectively). A significant dose interaction was also ob-
served for the neurons from young rabbits (F(4,20) 5 3.57; p ,
0.024). Finally, there was a significant difference of mean baseline
accommodation measures between the neurons from young and
aging rabbits (F(1,60) 5 10.60; p , 0.002) (Moyer et al., 1992).
Atropine partially reversed the effects of metrifonate
Atropine, by itself, had no significant effect on the biophysical
measurements (see Table 3). Atropine (1 mM) significantly re-
versed the action of metrifonate on accommodation (Fig. 1; see
Fig. 4). In the neurons from young rabbits, when atropine was
added to 50 mM metrifonate, the accommodation was returned to
that observed during baseline ( p , 0.028). However, atropine did
not return the AHP measures back to baseline ( p . 0.192).
Chronic metrifonate treatment increased
neuronal excitability
CA1 neurons from chronically metrifonate-treated rabbits were
more excitable than those from the vehicle-treated rabbits (Fig.
3). Typically, the neurons from aging rabbits exhibit a strong
accommodation, as illustrated in Figure 1A (see also Fig. 3A,
bottom panel; Table 1). The baseline accommodation measure-
ment was significantly reduced in neurons from the metrifonate-
Table 1. Biophysical properties of CA1 neurons from young and aging rabbits after bath application of metrifonate in vitro
Metrifonate (10 mM) Metrifonate (50 mM) Metrifonate (100 mM)
Baseline Postdrug p value Baseline Postdrug p value Baseline Postdrug p value
Young
Postburst AHP
Amplitude (mV) 23.62 6 0.68 23.07 6 0.72 0.006 (6) 24.33 6 0.55 23.04 6 0.33 0.007 (11) 22.04 20.87 (1)
Area (mVsec) 23.09 6 1.31 22.01 6 0.98 0.046 (6) 23.69 6 1.15 21.91 6 0.77 0.043 (11) 20.50 20.03 (1)
Duration (sec) 1.80 6 0.54 1.44 6 0.38 0.202 (6) 1.96 6 0.44 1.54 6 0.53 0.288 (11) 0.62 0.08 (1)
Accommodation 10.75 6 1.64 11.62 6 1.33 0.439 (6) 8.18 6 0.81 12.73 6 1.44 0.001 (11) 8.50 12.00 (1)
Input resistance (MV) 43.04 6 4.80 39.65 6 5.09 0.299 (6) 56.29 6 6.15 52.28 6 4.35 0.370 (11) 40.28 41.97 (1)
Metrifonate (50 mM) Metrifonate (100 mM) Metrifonate (200 mM)
Aging
Postburst AHP
Amplitude (mV) 24.94 6 0.47 24.12 6 0.46 0.009 (17) 25.37 6 0.63 23.92 6 0.70 0.002 (9) 24.58 6 0.72 22.83 6 1.08 0.028 (5)
Area (mVsec) 25.43 6 1.06 24.16 6 0.84 0.074 (17) 25.98 6 1.25 22.57 6 0.93 0.001 (9) 24.25 6 1.60 21.87 6 1.55 0.012 (5)
Duration (sec) 3.46 6 0.34 3.34 6 0.44 0.775 (17) 3.87 6 0.45 1.46 6 0.26 0.001 (9) 2.84 6 0.70 0.89 6 0.38 0.025 (5)
Accommodation 7.02 6 0.56 8.81 6 0.91 0.014 (17) 5.89 6 0.66 9.73 6 1.68 0.020 (8) 6.75 6 0.52 13.50 6 1.02 0.0001 (7)
Input resistance (MV) 43.53 6 2.54 47.53 6 2.31 0.034 (16) 37.14 6 2.30 37.43 6 3.77 0.849 (8) 43.62 6 6.88 40.68 6 3.55 0.454 (7)
The number in parentheses indicates the number of cells recorded. The data for young rabbits at 100 mM metrifonate is based on the one of five neurons that survived through
the drug application. The numbers in bold type indicate statistical significance using paired t test. The measurements are the mean 6 SEM.
Figure 3. Chronic, oral treatment with metrifonate
(12 mg/kg daily) in aging subjects significantly re-
duced the accommodation in CA1 neurons. A depicts
a typical example of the differing response to an 800
msec depolarizing current pulse used to obtain four
action potentials in the first 100 msec observed in
CA1 neurons from chronically metrifonate- (top) or
vehicle-treated (bottom) subjects. B, Mean baseline
accommodation was significantly reduced in neurons
from the chronic metrifonate-treated subjects as
compared with those from vehicle-treated subjects
(mean 6 SEM; **p , 0.01, unpaired t test).
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treated aging rabbits (F(1,45) 5 9.789; p , 0.003). The decreased
accommodation brought the baseline accommodation measure-
ments of these neurons to values similar to those from young,
untreated subjects; 8.76 6 0.71 action potentials vs 8.73 6 0.33
action potentials for the aging, treated and young, untreated
rabbits, respectively (F(1,102) 5 0.0019; p . 0.965). The baseline
AHP measurements were not significantly different between the
metrifonate- and vehicle-treated aging rabbits (F(1,45) 5 0.358;
p . 0.553).
The CA1 neurons from chronically metrifonate-treated aging
rabbits were not desensitized to the effects of bath application of
metrifonate ex vivo. Addition of metrifonate (50 mM) to the
perfusate significantly decreased the AHP peak amplitude and
accommodation in neurons from both chronically metrifonate-
( p , 0.004; p , 0.009, respectively) and vehicle-treated rabbits
( p , 0.012; p , 0.011, respectively) (Figs. 4, 5; Table 2). The
integrated area of the AHP was significantly reduced for the
neurons from metrifonate-treated rabbits ( p , 0.033). The dec-
rements were reversed with 1 mM atropine in the perfusate ( p ,
0.028 for AHP; p , 0.033 for accommodation; and p , 0.033 for
area; Figs. 4, 5; Table 2).
Chronic metrifonate treatment reduced
cholinesterase activity
The chronic metrifonate treatment significantly decreased the
RBC AChE activity of aging rabbits by 25% (24.62 6 3.62%; n 5
4; p , 0.021); no inhibition of AChE activity was observed in the
vehicle-treated, control subjects ( p . 0.241; n 5 3). The RBC
AChE activity was significantly different between the two treat-
ment groups (F(1,5) 5 28.79; p 5 0.003).
Carbachol increased neuronal excitability
Bath application of carbachol significantly increased the excitabil-
ity of CA1 neurons from both young and aging subjects, as
reported previously (Bernardo and Prince, 1982; Cole and Nicoll,
1983, 1984a,b; Potier et al., 1992; Taylor and Griffith, 1993;
Pedarzani and Storm, 1996). At 500 nM, the AHP amplitude was
reduced by .1.0 mV in CA1 neurons from both young (1.18 6
0.30 mV; p , 0.003) and aging (1.17 6 0.27 mV; p , 0.001)
subjects (Fig. 6, Table 3). The integrated area of the AHP was
significantly reduced for CA1 neurons from both age groups ( p ,
0.009 for young; p , 0.005 for aging). The duration of the AHP
was also significantly shortened for CA1 neurons from aging
subjects ( p , 0.034), and a trend for such a reduction was
observed in young ( p . 0.106).
Accommodation was significantly reduced in CA1 neurons
from both age groups. In CA1 neurons from aging subjects, the
number of action potentials elicited by a long depolarizing pulse
was nearly doubled after carbachol (500 nM) application ( p 5
0.0002). The effect on accommodation in CA1 neurons of young
subjects was not nearly as dramatic, although it was significantly
reduced, ( p 5 0.0010; Fig. 6, Table 3). This may be caused by the
fact that the baseline accommodation was stronger in CA1 neu-
Figure 4. Bath application of 50 mM metrifonate to CA1 neurons from chronic metrifonate-treated subjects further significantly decreased the
accommodation ( B). This effect was significantly reversed by adding 1 mM atropine to the perfusate ( C) (same neuron in A–C). The mean increase (with
50 mM metrifonate) and decrease (with 50 mM metrifonate and 1 mM atropine) in the number of action potentials elicited in CA1 neurons from the chronic
metrifonate-treated subjects are illustrated in D (mean 6 SEM; **p , 0.01; paired t tests).
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rons of aging subjects (F(1,23) 5 6.19; p , 0.021) (Moyer et al.,
1992).
Eserine increased neuronal excitability
The cholinesterase inhibitor eserine significantly decreased the
AHP and spike frequency accommodation in CA1 neurons from
young subjects in a manner similar to that previously reported
(Cole and Nicoll, 1984a,b; Halliwell 1990). The AHP peak am-
plitude was significantly reduced when 1 or 5 mM eserine was
added to the perfusate ( p , 0.007; p , 0.018, respectively; Table
3). The accommodation was significantly decreased for all con-
centrations of eserine tested ( p values , 0.01; Table 3). Also, the
input resistance was similarly increased with a significant effect
observed for 1 mM eserine ( p , 0.018).
No significant changes were observed with time
Normal aCSF was used as one of the blind perfusates on CA1
neurons from young and aging subjects to determine possible
neuronal deterioration over time in the recording chamber (Table
3). No significant changes were observed in CA1 neurons from
either young or aging subjects over time.
DISCUSSION
The present set of experiments revealed that (1) bath-applied
metrifonate significantly increases neuronal excitability in vitro;
(2) chronic metrifonate treatment increases the basal level of
neuronal excitability ex vivo; (3) neurons from chronically
metrifonate-treated subjects remain sensitive to bath application
of metrifonate, i.e., no “saturating” effect is observed with chronic
treatment; and (4) the excitability changes observed with metri-
fonate mimic that observed with the cholinergic agonist carbachol
and the cholinesterase inhibitor eserine, and could be reversed by
atropine, thus metrifonate acts primarily via muscarinic cholin-
ergic neurotransmission.
A higher concentration of metrifonate was necessary to signif-
icantly increase the neuronal excitability of CA1 neurons of aging
rabbits compared with that of the young (Fig. 2, Table 1). This
suggests an apparent shift in the efficacy of metrifonate for the
neurons of aging rabbits. Likewise, a ceiling effect of metrifonate
(tested up to 200 mM) was not observed in the neurons from aging
rabbits. In the neurons from young rabbits, 100 mM metrifonate
depolarized the neurons with high-frequency bursts of action
potentials, leading to membrane potential instability and eventual
cell death. However, no such effects were observed in the neurons
from aging rabbits. If anything, a greater reduction of AHP and
accommodation was observed with higher concentration of met-
rifonate in the neurons from aging rabbits. One possible contrib-
uting factor to these effects may be the reduced level of endoge-
nous ACh in vivo in aging subjects (Scali et al., 1997; Vannucchi
et al., 1997), which may translate into less endogenous ACh
present in the tissue of aging subjects in vitro. Scali and colleagues
(1997) report that 80 mg/kg of metrifonate given to young and
aging rats produced unequal increase in ACh levels in the hip-
pocampus in vivo: a threefold increase in the young compared
with only a 30% increase in the aged. Thus, a higher dose of
metrifonate may be needed to allow cholinergic reduction of the
larger AHPs and stronger accommodations that are generally
observed in CA1 neurons from aging subjects (see Results; Land-
field and Pitler, 1984; Moyer et al., 1992).
Chronic metrifonate treatment caused a clear reduction of
RBC AChE inhibition similar to the effect previously reported by
Kronforst-Collins et al. (1997b). CA1 neurons from the
metrifonate-treated rabbits were found to be more excitable,
resembling neurons from the young rabbits. Furthermore, the
AHP and accommodation of neurons from chronically
metrifonate-treated rabbits remained sensitive to the bath appli-
cation of metrifonate (Fig. 4). This observation is consistent with
the results obtained by Hinz et al. (1998) that chronic metrifonate
treatment did not (1) alter the ACh synthesis rate, (2) change the
muscarinic or nicotinic receptor binding, or (3) affect the mono-
amines in the brain (Soininen et al., 1990). This is contrary to the
effects of chronic treatment with tacrine, which increased dopa-
minergic and serotoninergic metabolism (Soininen et al., 1990)
and decreased binding to high-affinity choline uptake and nico-
tinic and muscarinic receptors (Sihver et al., 1997).
Numerous experiments have examined the modulatory role of
cholinergic inputs in various learning and memory tasks, espe-
cially in aging subjects. For example, experiments with the central
cholinergic blocker, scopolamine, demonstrated that humans (So-
lomon et al., 1993) and rabbits (Harvey et al., 1983) were im-
paired in learning delay (nonhippocampus-dependent) eyeblink
conditioning when pretreated with scopolamine. This impairment
is hypothesized to be mediated by the hippocampus, because
scopolamine treatment did not impair hippocampal-lesioned sub-
jects from acquiring delay eyeblink conditioning (Solomon et al.,
1983), but did prevent rabbits from acquiring trace
(hippocampus-dependent) eyeblink conditioning (Kaneko and
Figure 5. Bath application of 50 mM metrifonate significantly decreased
the AHP peak amplitude (A) and increased the number of action poten-
tials elicited during the accommodation pulse (B) in CA1 neurons from
both the chronically metrifonate- and vehicle-treated, aging subjects. The
decrease in accommodation was significantly reversed by addition of 1 mM
atropine to the perfusate for the CA1 neurons from metrifonate-treated,
aging subjects (mean 6 SEM; *p , 0.05; **p , 0.01; paired t tests).
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Thompson, 1997). Treatment with metrifonate reversed the def-
icits observed in acquiring the passive and active avoidance,
Morris water maze, and radial-arm maze tasks by normal aging,
medial-septum lesioned, or scopolamine-treated subjects (Riek-
kinen et al., 1996, 1997; van der Staay et al., 1996; Itoh et al., 1997;
Dachir et al., 1997). Also, in double-blind clinical trials, metri-
fonate treatment alleviated the cognitive impairments observed
in AD patients with minimal side-effects (Cummings et al., 1998;
Morris et al., 1998; Pettigrew et al., 1998).
We hypothesize that the increased neuronal excitability de-
scribed here underlies the learning enhancement we have ob-
served with chronic metrifonate treatment in aging rabbits
(Kronforst-Collins et al., 1997a,b). The reductions of the AHP
and accommodation are of particular significance because they
are well correlated with learning (Moyer et al., 1996; Thompson
et al., 1996b). Both are reduced in hippocampal neurons from
rabbits that acquire the trace eyeblink conditioning task, but not
in the control animals or in animals that are trained but fail to
acquire the task (Disterhoft et al., 1996; Moyer et al., 1996;
Thompson et al., 1996b). The AHP and accommodation changes
also parallel the time course of hippocampal function. The hip-
pocampus is required for the acquisition, but not long-term recall,
of trace eyeblink conditioning (Kim et al., 1995). Changes in
neuronal excitability were observed immediately after acquisi-
tion, and the neuronal changes returned to that of the controls
(presumed basal levels) within 7 d, whereas the behavioral per-
formance remained asymptotic for months (Moyer et al., 1996;
Thompson et al., 1996b). By that time memory storage was
presumably mediated through the neocortex and/or associated
circuitry. Similar results were obtained with the L-type calcium
channel blocker, nimodipine, providing further support for this
neuronal excitability hypothesis. Nimodipine facilitated acquisi-
tion of trace eyeblink conditioning and increased neuronal excit-
ability (reduced the AHP and accommodation) (Deyo et al.,
1989; Moyer et al., 1992; Kowalska and Disterhoft, 1994). This is
similar to the situation that we find here with chronic metrifonate
treatment: enhanced acquisition rate of trace eyeblink condition-
ing, tightly coupled with increased CA1 excitability ex vivo.
The importance of cholinergic modulation of synaptic trans-
mission in the hippocampus and neocortex during learning and
recall of novel associations have been emphasized by Hasselmo et
al. (1992), Hasselmo and Bower (1992), and Hasselmo and
Schnell (1994). They posit that the learning rate is increased and
Table 2. Biophysical properties of CA1 neurons from aging rabbits that have been chronically treated with either 12 mg/kg metrifonate or vehicle
n
Postburst afterhyperpolarization
Accommodation (# of
action potentials)
Input resistance
(MV)Amplitude (mV) Area (mVsec) Duration (sec)
12 mg/kg metrifonate
aCSF 19 24.38 6 0.41 23.87 6 0.59 2.82 6 0.35 8.76 6 0.71 42.46 6 2.57
Metrifonate (50 mM) 14 23.80 6 0.49 23.18 6 0.58 2.69 6 0.42 10.75 6 1.10 51.86 6 2.33
Metrifonate (50 mM)
1 Atropine (1 mM) 15 24.12 6 0.47 23.72 6 0.61 3.31 6 0.35 9.45 6 0.91 43.13 6 2.62
Vehicle
aCSF 28 24.70 6 0.34 24.81 6 0.70 3.16 6 0.25 6.40 6 0.40 44.94 6 1.95
Metrifonate (50 mM) 17 24.15 6 0.47 24.19 6 0.88 3.31 6 0.43 9.02 6 0.93 47.53 6 2.31
Metrifonate (50 mM)
1 Atropine (1 mM) 13 24.78 6 0.51 25.25 6 1.21 3.82 6 0.42 7.37 6 0.67 42.12 6 4.26
The neurons were subjected to a bath application of metrifonate (50 mM) followed by metrifonate plus atropine (1 mM) after the initial baseline measurements were recorded.
As mentioned in Materials and Methods, the neurons were given 10 min of rest /stabilization periods during each change of the bath perfusate. n indicates the number of cells
recorded. The measurements are the mean 6 SEM.
Figure 6. Bath application of 500 nM carbachol significantly increased
CA1 excitability in neurons from both young and aging subjects. The
mean AHP peak amplitude was significantly reduced by 500 nM carbachol
(striped bars) as compared with the baseline (open bars) measurements
(A). The mean accommodation was significantly reduced by 500 nM
carbachol (striped bars) as compared with the baseline (open bars) mea-
surements ( B) (mean 6 SEM; **p , 0.01; ***p , 0.001; paired t tests).
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the maintenance of memory is prolonged by cholinergic suppres-
sion of the intrinsic fiber synapses in the hippocampus and cortex
during learning. They further postulate that there is a direct
regulation of ACh concentration in the hippocampus: during
learning of new associations, the cholinergic input is high; during
recall of learned associations, the cholinergic input is low (Has-
selmo and Schnell, 1994). Their hypotheses of the cholinergic
modulation fits very well with what may be occurring in the
hippocampus of rabbits during trace eyeblink conditioning. As
the rabbits are initially learning to associate the tone with the
airpuff (novel association), the cholinergic input into the hip-
pocampus would be increased, thereby increasing the neuronal
excitability of the pyramidal neurons (AHP and accommodation
reductions). This boost of increased neuronal excitability with
ACh may be crucial for aging rabbits (that are usually impaired in
learning the trace eyeblink conditioned response) (Thompson et
al., 1996a) to learn associative tasks: slow EPSPs and CA1 pop-
ulation EPSPs are significantly reduced in aging subjects com-
pared with the young (Landfield et al., 1986; Barnes et al., 1992;
Potier et al., 1992; Taylor and Griffith, 1993). Soon after acquiring
the tone–airpuff association, the cholinergic input to the hip-
pocampus would begin to decrease, but the neuronal excitability
of the pyramidal neurons would remain increased for a period of
time (Moyer et al., 1996; Thompson et al., 1996b). With the steady
decline of the cholinergic input to the hippocampus, the neuronal
excitability of the pyramidal neurons would return to the basal
state. But the association would be maintained over time, because
by that point the memory for the association would have been
stored in the neocortex, as rabbits tested months after the training
sessions perform asymptotically on trace eyeblink conditioning
(Moyer et al., 1996; Thompson et al., 1996b). In the behavioral
experiments conducted by Kronforst-Collins et al. (1997b), met-
rifonate treatment clearly facilitated acquisition of trace eyeblink
conditioning and decreased AChE activity (thus, increased ACh
throughout the brain) in aging rabbits. After acquiring the task
and after metrifonate treatment was ceased, the metrifonate-
treated rabbits still displayed asymptotic behavior (Kronforst-
Collins et al., 1997b), suggesting that the cholinergic input was
important for acquisition but not the recall of the association.
Recently, Zhang et al. (1997) have demonstrated that AChE
inhibition led to an increased (as long as 30 sec) temporal “win-
dow” for ACh to modulate the current underlying the slow AHP
(IsAHP) (i.e., reduce the AHP) in CA1 neurons in vitro after a
train of cholinergic afferent stimulation in CA1 stratum radiatum;
without the AChE inhibitors, the window was ,5 sec. They
further speculated that the window may be shorter in vivo. They
have also demonstrated that the stimulation of the cholinergic
afferents must precede the CA1 depolarization (activity) by 400–
1500 msec to achieve the IsAHP reduction (Zhang et al., 1996). It
is possible that metrifonate in vivo increases the ACh level in the
synapses of pyramidal neurons, prolonging the temporal window
for ACh modulation of pyramidal neuronal activity and resulting
in an increased signal-to-noise ratio that facilitates the acquisition
of various behavioral tasks in aging and cholinergic-deficient (AD
and medial–septal or scopolamine lesioned) subjects. In trace
eyeblink conditioning, where a stimulus-free trace period sepa-
rates the conditioned and unconditioned stimuli, the AChE inhi-
bition should increase the ACh present in the synapses of hip-
pocampal pyramidal neurons during the trace period. This would
help the subject to associate the conditioned and unconditioned
stimuli and enhance the acquisition rate in aging subjects.
In summary, the increased neuronal excitability (as evidenced
by the reduced postburst afterhyperpolarization and spike fre-
quency adaptation) of hippocampal pyramidal neurons may be
one of the underlying mechanisms by which the hippocampus
stores information during associative learning. As previously
demonstrated, the AHP and accommodation are reduced in
hippocampal neurons when a subject learns an associative task
but not in subjects that did not learn the same associative task
(Moyer et al., 1996; Thompson et al., 1996b). Furthermore, the
AHP and accommodation are greater in neurons from aging
subjects than from the young (Landfield and Pitler, 1984; Moyer
et al., 1992); in the same aging population, a severe impairment in
learning associative tasks (such as trace eyeblink conditioning) is
observed (Thompson et al., 1996a). The learning deficit observed
in the aging population is alleviated by pharmacological agents,
such as metrifonate (Kronforst-Collins et al., 1997a,b) and the
L-type calcium channel blocker nimodipine (Deyo et al., 1989;
Kowalska et al., 1994). These same two compounds have been
demonstrated to increase hippocampal pyramidal neuronal excit-
ability (reduced AHP and accommodation) in vitro (see results
and Moyer et al., 1992). Thus, increased neuronal excitability of
hippocampal pyramidal neurons may be one mechanism by which
memory is transiently stored in the hippocampus during the early
stages of learning before being transferred to the neocortex for
Table 3. Mean change of biophysical properties of CA1 neurons from young and aging rabbits after bath application of carbachol, eserine, atropine,
or aCSF in vitro
n
Postburst afterhyperpolarization
Duration (sec)
Accommodation
(# of action potentials)
Input resistance
(MV)Amplitude (mV) % AHP D Area (mVsec)
Young
aCSF 13 20.40 6 0.35 210.44 6 4.93 20.78 6 0.79 0.37 6 0.71 0.63 6 0.40 1.28 6 2.20
Atropine (1 mM) 5 0.11 6 0.48 21.89 6 11.93 20.14 6 0.83 0.27 6 0.28 1.25 6 0.69 2.56 6 7.05
Carbachol (500 nM) 11 21.18 6 0.30** 229.25 6 7.30 21.74 6 0.54** 21.23 6 0.69 4.74 6 0.99*** 3.45 6 2.52
Eserine (500 nM) 7 20.75 6 0.45 212.16 6 11.53 21.36 6 0.64 20.91 6 0.39 2.11 6 0.60** 2.41 6 3.48
Eserine (1 mM) 14 20.38 6 0.12** 216.38 6 4.31 20.51 6 0.36 20.50 6 0.36 2.12 6 0.48*** 3.65 6 1.30*
Eserine (5 mM) 7 21.07 6 0.33* 227.62 6 7.07 21.83 6 0.62* 20.85 6 0.40 4.81 6 0.69*** 22.03 6 2.38
Aging
aCSF 3 0.48 6 0.35 14.87 6 10.05 20.58 6 0.99 21.52 6 0.57 1.11 6 0.78 21.86 6 0.92
Carbachol (500 nM) 14 21.17 6 0.27*** 222.74 6 5.82 22.30 6 0.68** 20.89 6 0.38* 4.80 6 0.90*** 3.30 6 2.27
n indicates the number of cells recorded. The numbers in bold type indicate statistical significance using paired t test. The measurements are the mean 6 SEM (*p , 0.05;
**p , 0.01; ***p , 0.001; paired t tests).
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more permanent storage. Pharmacological agents that cause an
excitability increase comparable to that which occurs during the
acquisition process in young subjects appear to enhance learning
in normal aging subjects and perhaps in those undergoing a
neurodegenerative process such as Alzheimer’s disease.
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